VERAXA Biotech and Secarna Pharmaceuticals Partner on AOCs

ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY - September 30, 2025 -- VERAXA Biotech, an emerging leader in novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH), and Secarna Pharmaceuticals GmbH & Co. KG, a company focused on oligonucleotide therapeutics, announced a strategic research collaboration. This partnership aims to develop next-generation antibody oligonucleotide conjugates (AOCs) to create novel targeted therapies for autoimmune and chronic immune diseases.

Antibody oligonucleotide conjugates (AOCs) combine the precise targeting of monoclonal antibodies with the versatile functional capabilities of oligonucleotides. This innovative approach allows for the direct delivery of therapeutic oligonucleotides to specific disease-relevant cells, thereby significantly enhancing treatment efficacy and reducing unwanted off-target effects. Such targeted delivery is crucial for modulating gene expression with high precision, offering substantial benefits in the treatment of complex conditions, particularly those affecting the immune system.

... Read on — Members only